Allianz Asset Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-9,100
| Closed | -$805K | – | 2033 |
|
|
2025
Q1 | $805K | Sell |
9,100
-4,700
| -34% | -$458K | ﹤0.01% | 1733 |
|
|
2024
Q4 | $1.2M | Buy |
13,800
+6,600
| +92% | +$605K | ﹤0.01% | 1588 |
|
|
2024
Q3 | $666K | Buy |
7,200
+1,400
| +24% | +$139K | ﹤0.01% | 1775 |
|
|
2024
Q2 | $625K | Sell |
5,800
-2,900
| -33% | -$290K | ﹤0.01% | 1758 |
|
|
2024
Q1 | $825K | Buy |
8,700
+1,200
| +16% | +$103K | ﹤0.01% | 1473 |
|
|
2023
Q4 | $692K | Sell |
7,500
-6,800
| -48% | -$441K | ﹤0.01% | 1745 |
|
|
2023
Q3 | $718K | Hold |
14,300
| – | – | ﹤0.01% | 1807 |
|
|
2023
Q2 | $904K | Buy |
+14,300
| New | +$777K | ﹤0.01% | 1569 |
|
|
2022
Q3 | – | Sell |
-36,591
| Closed | -$1.85M | – | 1912 |
|
|
2022
Q2 | $1.85M | Sell |
36,591
-25,557
| -41% | -$1.5M | ﹤0.01% | 1446 |
|
|
2022
Q1 | $3.97M | Sell |
62,148
-23,098
| -27% | -$1.66M | ﹤0.01% | 1315 |
|
|
2021
Q4 | $9.15M | Sell |
85,246
-8,988
| -10% | -$940K | 0.01% | 1024 |
|
|
2021
Q3 | $9.69M | Buy |
94,234
+34,970
| +59% | +$3.26M | 0.01% | 1028 |
|
|
2021
Q2 | $5.21M | Buy |
59,264
+3,159
| +6% | +$289K | ﹤0.01% | 1089 |
|
|
2021
Q1 | $5.46M | Buy |
56,105
+1,003
| +2% | +$100K | 0.01% | 1025 |
|
|
2020
Q4 | $6.18M | Buy |
+55,102
| New | +$5.81M | 0.01% | 981 |
|
|
2020
Q3 | – | Sell |
-8,833
| Closed | -$689K | – | 1922 |
|
|
2020
Q2 | $689K | Sell |
8,833
-2,171
| -20% | -$147K | ﹤0.01% | 1952 |
|
|
2020
Q1 | $643K | Sell |
11,004
-23,804
| -68% | -$1.53M | ﹤0.01% | 1959 |
|
|
2019
Q4 | $2.79M | Sell |
34,808
-6,456
| -16% | -$483K | ﹤0.01% | 1736 |
|
|
2019
Q3 | $3.03M | Sell |
41,264
-154
| -0.4% | -$13.3K | ﹤0.01% | 1658 |
|
|
2019
Q2 | $3.91M | Buy |
41,418
+4,215
| +11% | +$348K | ﹤0.01% | 1614 |
|
|
2019
Q1 | $2.98M | Buy |
37,203
+4,174
| +13% | +$308K | ﹤0.01% | 1679 |
|
|
2018
Q4 | $1.75M | Sell |
33,029
-5,744
| -15% | -$349K | ﹤0.01% | 1813 |
|
|
2018
Q3 | $3.03M | Sell |
38,773
-3,948
| -9% | -$274K | ﹤0.01% | 1785 |
|
|
2018
Q2 | $2.71M | Buy |
42,721
+4,053
| +10% | +$323K | ﹤0.01% | 1812 |
|
|
2018
Q1 | $3.55M | Sell |
38,668
-4,675
| -11% | -$403K | ﹤0.01% | 1677 |
|
|
2017
Q4 | $3.27M | Buy |
43,343
+36,117
| +500% | +$2.54M | ﹤0.01% | 1810 |
|
|
2017
Q3 | $503K | Buy |
+7,226
| New | +$386K | ﹤0.01% | 2416 |
|
|
2017
Q2 | – | Sell |
-37,336
| Closed | -$1.49M | – | 2608 |
|
|
2017
Q1 | $1.49M | Sell |
37,336
-197
| -0.5% | -$7.05K | ﹤0.01% | 2101 |
|
|
2016
Q4 | $1.05M | Sell |
37,533
-4,897
| -12% | -$148K | ﹤0.01% | 2195 |
|
|
2016
Q3 | $1.26M | Buy |
+42,430
| New | +$1.05M | ﹤0.01% | 2152 |
|
Other funds holding BPMC
PCM
UOC
Allianz Asset Management's BPMC Position: Q2 2025 in Review
Allianz Asset Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 9,100 shares — an estimated $805K sold.
Allianz Asset Management first reported a position in BPMC in Q3 2016 and held it in 30 quarters. The position peaked at $9.69M in Q3 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.
- Allianz Asset Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
- Allianz Asset Management sold 9,100 Blueprint Medicines shares in Q2 2025, an estimated $805K.
- Allianz Asset Management first reported a position in Blueprint Medicines in Q3 2016 and held it in 30 quarters.
- Allianz Asset Management's Blueprint Medicines position peaked at $9.69M in Q3 2021.
- 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.
Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.